Comparison of NSAID consumption in Slovakia, Finland and Norway

Bratislava Medical Journal

Volumn 109, Issue 8, 2008, Pages 370-373

  Hudec, R ^a   Kriska, M ^a   Bozekova, L ^a   Foltan, V ^b  

^a Bratislava   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

Author keywords

Diclofenac; Ibuprofen; Nimesulide; NSAID consumption; Piroxicam; Statistic

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; DRUG UTILIZATION; FINLAND; HUMAN; NORWAY; SLOVAKIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG UTILIZATION; FINLAND; HUMANS; NORWAY; SLOVAKIA;

EID: 57049147410     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232-235.
2. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Brit Med J 2006; 332 (7553): 1302-1308.
3. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J Amer Med Ass 2006; 296 (13): 1633-1644.
4. Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 2007; 46 (3): 435-438.
5. Singh G, Wu O, Langhorne P et al. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006; 8 (5): R153.
6. Henry D, Lim LL, Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Brit Med J 1996; 312: 1563-1566.
7. Dieppe P, Bardett C, Davey P, Doyal L, Ebrahim S. Balancing benefits and harms:the example of non-steroidal anti-inflammatory drugs. Brit Med J 2004; 329: 31-34.
8. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3 (5): 489-498.
9. The European Medicines Agency (EMEA).Available at: www.emea.europa.eu. Accesed on April 2008
10. Morrison A, Ramey DR, van Adelsberg J et al. Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin 2007; 23 (10): 2395-2404.
11. Bergman U, Popa C, Tomson Y, Wettermark B, Einarson TR, Aberg H, Sjöquist F. Drug utilisation 90 % - a simple metod for assessing the duality of drug prescribing. Eur J Clin Pharmacol 1998; 54: 113-118.
12. Finnish Statistics on Medicines. National Agency for Medicines. Available at www.nam.fi/english/medicines/drug. Accessed in April 2008
13. Norwegian Institute of Public Health. Drug consumption in Norway 2002-2006. Oslo, March 2007. Available at: wwwlegemiddelforbruk.no/ english. Accessed in February 2008.
14. Bergman U, Andersen M, Vaccheri A, Bjerrum L, Wettermark B, Montanaro N. Deviations from evidence-based prescribing of non-steroidal anti-inflammatory drugs in three European Regions. Eur J Clin Pharmacol 2000; 56: 269-272.
15. Lewis SC, Langman MJ, Laporte JR et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Brit J Clin Pharmacol 2002; 54 (3): 320-326.
16. Sbeit W, Krivoy N, Shiller M, Farah R, Cohen HI, Struminger L, Reshef R. Nimesulide induced acute hepatitis. Ann Pharmacothe 2001; 35: 1049-1051.
17. Schattner A, Sokolovskaya N, Cohen J. Fatal hepatitis and renal failure during treatment with nimesulide. J Int Med 2000; 247: 153-155.
18. Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Brit J Rheumatol 1998; 37 (9): 937-945.